ProKidney FY2026 Earnings Forecast Cut by HC Wainwright

ProKidney Corp. (NASDAQ:PROK – Free Report) – Analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of ProKidney in a note issued to investors on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.63) per share for the year, down from their previous estimate of ($0.52). The consensus estimate for ProKidney’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for ProKidney’s Q4 2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.58) EPS and FY2029 earnings at ($0.42) EPS.

ProKidney (NASDAQ:PROK – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.12 million.

A number of other analysts have also issued reports on PROK. Citigroup decreased their price target on ProKidney to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, October 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, ProKidney presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Read Our Latest Stock Report on PROK

ProKidney Trading Down 0.5%

ProKidney stock opened at $1.04 on Tuesday. The stock has a fifty day moving average price of $1.51 and a 200 day moving average price of $1.76. ProKidney has a 52 week low of $0.87 and a 52 week high of $2.65.

Insider Activity at ProKidney

In related news, Director Brian Pereira sold 222,948 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $1.42, for a total value of $316,586.16. Following the transaction, the director directly owned 54,103 shares of the company’s stock, valued at approximately $76,826.26. This trade represents a 80.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 500,000 shares of company stock worth $715,000. Corporate insiders own 39.83% of the company’s stock.

Institutional Investors Weigh In On ProKidney

A number of institutional investors have recently added to or reduced their stakes in PROK. Simplify Asset Management Inc. acquired a new stake in shares of ProKidney in the third quarter valued at about $803,000. Renaissance Technologies LLC raised its holdings in shares of ProKidney by 39.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,250,794 shares of the company’s stock valued at $2,239,000 after buying an additional 355,089 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in ProKidney by 14.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,847,749 shares of the company’s stock worth $3,769,000 after acquiring an additional 236,056 shares in the last quarter. Bank of America Corp DE lifted its position in ProKidney by 6.7% during the 1st quarter. Bank of America Corp DE now owns 753,412 shares of the company’s stock worth $1,349,000 after acquiring an additional 47,268 shares in the last quarter. Finally, AXQ Capital LP acquired a new position in ProKidney during the 2nd quarter worth approximately $76,000. Hedge funds and other institutional investors own 51.59% of the company’s stock.

ProKidney Company Profile

(Get Free Report)

ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.

Read More

Earnings History and Estimates for ProKidney (NASDAQ:PROK)

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.